Xsensio raises $7M Series A to advance healthtech clinical integration

Swiss healthtech company Xsensio SA has secured $7 million in an oversubscribed Series A financing round to accelerate the clinical rollout of its wearable biochemical monitoring platform. The investment, led by WI Harper Group with participation from Privilège Ventures and the European Innovation Council, will support product validation, engineering expansion, and preparation for broader healthcare deployment.

Funding to support clinical integration

The new capital marks an important step for Xsensio as it transitions from research and early development toward real-world medical implementation. Company executives said the funds will be directed primarily toward clinical studies, regulatory progress, and scaling technical capabilities required for deployment in healthcare environments.

Unlike many wearable devices that focus on physical metrics such as heart rate or movement, Xsensio’s platform is designed to monitor biochemical markers continuously. This approach aims to provide physicians with a more dynamic view of patient physiology, capturing trends over time rather than relying solely on periodic lab tests.

The Series A round attracted international backing, reflecting broader investor interest in next generation biosensing. By closing the round above its initial target, the company demonstrated confidence from both new and existing investors in the commercial potential of continuous biochemical monitoring.

Technology designed for continuous biochemical data

At the center of the company’s strategy is its Lab-on-Skin™ technology, a miniaturized sensing system engineered to measure multiple biomarkers in near real time. The wearable device is intended to sit comfortably on the skin while collecting biochemical information that may help clinicians assess changes in patient condition more quickly.

To strengthen its hardware capabilities, Xsensio announced a strategic collaboration with Texas Instruments. The partnership is focused on semiconductor integration and scalable manufacturing, leveraging Texas Instruments’ expertise in CMOS and chip development to support reliable, cost-effective production.

Company leadership has emphasized that combining proprietary biosensing materials with advanced semiconductor design is central to achieving both precision and scalability. By refining this integration, Xsensio aims to bring laboratory-level biochemical insights into wearable form factors suitable for clinical use.

Positioning within a growing healthtech sector

The broader healthcare industry has shown increasing interest in continuous monitoring technologies, particularly as remote care and personalized medicine expand. Traditional diagnostic workflows often depend on isolated measurements taken during hospital visits. Continuous biosensing seeks to complement these methods by delivering ongoing physiological data that may detect changes earlier.

Founded in Lausanne, Switzerland, Xsensio emerged from academic research focused on advanced materials and nanoelectronics. Over time, the company has evolved toward translating that research into commercially viable medical technology.

The wearable biosensing field remains competitive, with companies pursuing various approaches to glucose tracking, hydration monitoring, and inflammatory marker detection. Xsensio’s emphasis on multiplex biochemical sensing differentiates its platform within the sector.

With $7 million in Series A funding secured, Xsensio SA is advancing from technical development toward clinical application. Backed by international investors and strengthened by its collaboration with Texas Instruments, the company is positioning its continuous biosensing technology as a potential tool for more data-driven healthcare decision-making. If clinical validation progresses as planned, the platform could contribute to a shift toward more continuous and personalized patient monitoring.